Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-041216
Filing Date
2021-08-05
Accepted
2021-08-05 08:33:47
Documents
57
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q agle-10q_20210630.htm   iXBRL 10-Q 2913098
2 EX-31.1 agle-ex311_6.htm EX-31.1 16032
3 EX-31.2 agle-ex312_183.htm EX-31.2 15981
4 EX-32.1 agle-ex321_7.htm EX-32.1 7048
5 EX-32.2 agle-ex322_184.htm EX-32.2 6983
  Complete submission text file 0001564590-21-041216.txt   8326161

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA agle-20210630.xsd EX-101.SCH 41580
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20210630_cal.xml EX-101.CAL 45268
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20210630_def.xml EX-101.DEF 125704
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20210630_lab.xml EX-101.LAB 327614
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20210630_pre.xml EX-101.PRE 240646
11 EXTRACTED XBRL INSTANCE DOCUMENT agle-10q_20210630_htm.xml XML 1586156
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37722 | Film No.: 211146499
SIC: 2834 Pharmaceutical Preparations